Use of Buserelin depot, a gonadotropin-releasing hormone agonist, in the treatment of prostate cancer
Buserelin is one of the first synthetic gonadotropin-releasing hormone agonists. The R.M. Fronshtein Clinic of Urology, I.M. Sechenov First Moscow State Medical University, has experience in using Buserelin depot in 32 patients with metastatic prostate cancer. The results of using Buserelin depot fo...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2014-12-01
|
| Series: | Андрология и генитальная хирургия |
| Subjects: | |
| Online Access: | https://agx.abvpress.ru/jour/article/view/110 |
| _version_ | 1827992443205713920 |
|---|---|
| author | L. M. Rapoport Yu. L. Demidko |
| author_facet | L. M. Rapoport Yu. L. Demidko |
| author_sort | L. M. Rapoport |
| collection | DOAJ |
| description | Buserelin is one of the first synthetic gonadotropin-releasing hormone agonists. The R.M. Fronshtein Clinic of Urology, I.M. Sechenov First Moscow State Medical University, has experience in using Buserelin depot in 32 patients with metastatic prostate cancer. The results of using Buserelin depot for 12 months are described. There was a significant reduction in prostate-specific antigen levels in the entire group.Twenty-seven (84.4 %) patients could achieve tumor stabilization. Twenty (62.5 %) of the 32 patients treated with Buserelin depot at the Clinic of Urology showed decreased residual urine; 9 (28.1%) had no changes and 3 (9.4 %) displayed increased residual urine. The administration of the drug caused significant bone pain relief in 76.5 % of the cases.All the Buserelin depot-treated patients satisfactorily tolerated the given treatment. There was either concomitant disease progression or treatment discontinuation in none of the cases. Thus, Buserelin depot proved to be an effective drug with a good safety profile. |
| first_indexed | 2024-04-10T03:54:18Z |
| format | Article |
| id | doaj.art-dee000a6df5a45b3bcbaa0e81d5be69d |
| institution | Directory Open Access Journal |
| issn | 2070-9781 |
| language | Russian |
| last_indexed | 2024-04-10T03:54:18Z |
| publishDate | 2014-12-01 |
| publisher | ABV-press |
| record_format | Article |
| series | Андрология и генитальная хирургия |
| spelling | doaj.art-dee000a6df5a45b3bcbaa0e81d5be69d2023-03-13T07:15:07ZrusABV-pressАндрология и генитальная хирургия2070-97812014-12-01153747910.17650/2070-9781-2014-3-74-79104Use of Buserelin depot, a gonadotropin-releasing hormone agonist, in the treatment of prostate cancerL. M. Rapoport0Yu. L. Demidko1I.M. Sechenov First Moscow State Medical University, Ministry of Health of RussiaI.M. Sechenov First Moscow State Medical University, Ministry of Health of RussiaBuserelin is one of the first synthetic gonadotropin-releasing hormone agonists. The R.M. Fronshtein Clinic of Urology, I.M. Sechenov First Moscow State Medical University, has experience in using Buserelin depot in 32 patients with metastatic prostate cancer. The results of using Buserelin depot for 12 months are described. There was a significant reduction in prostate-specific antigen levels in the entire group.Twenty-seven (84.4 %) patients could achieve tumor stabilization. Twenty (62.5 %) of the 32 patients treated with Buserelin depot at the Clinic of Urology showed decreased residual urine; 9 (28.1%) had no changes and 3 (9.4 %) displayed increased residual urine. The administration of the drug caused significant bone pain relief in 76.5 % of the cases.All the Buserelin depot-treated patients satisfactorily tolerated the given treatment. There was either concomitant disease progression or treatment discontinuation in none of the cases. Thus, Buserelin depot proved to be an effective drug with a good safety profile.https://agx.abvpress.ru/jour/article/view/110prostate cancersynthetic gonadotropin-releasing hormone agonistsbuserelin depot |
| spellingShingle | L. M. Rapoport Yu. L. Demidko Use of Buserelin depot, a gonadotropin-releasing hormone agonist, in the treatment of prostate cancer Андрология и генитальная хирургия prostate cancer synthetic gonadotropin-releasing hormone agonists buserelin depot |
| title | Use of Buserelin depot, a gonadotropin-releasing hormone agonist, in the treatment of prostate cancer |
| title_full | Use of Buserelin depot, a gonadotropin-releasing hormone agonist, in the treatment of prostate cancer |
| title_fullStr | Use of Buserelin depot, a gonadotropin-releasing hormone agonist, in the treatment of prostate cancer |
| title_full_unstemmed | Use of Buserelin depot, a gonadotropin-releasing hormone agonist, in the treatment of prostate cancer |
| title_short | Use of Buserelin depot, a gonadotropin-releasing hormone agonist, in the treatment of prostate cancer |
| title_sort | use of buserelin depot a gonadotropin releasing hormone agonist in the treatment of prostate cancer |
| topic | prostate cancer synthetic gonadotropin-releasing hormone agonists buserelin depot |
| url | https://agx.abvpress.ru/jour/article/view/110 |
| work_keys_str_mv | AT lmrapoport useofbuserelindepotagonadotropinreleasinghormoneagonistinthetreatmentofprostatecancer AT yuldemidko useofbuserelindepotagonadotropinreleasinghormoneagonistinthetreatmentofprostatecancer |